These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 34442713)
21. The impact of probiotics, prebiotics, and synbiotics on the biochemical, clinical, and immunological markers, as well as on the gut microbiota of obese hosts. da Silva TF; Casarotti SN; de Oliveira GLV; Penna ALB Crit Rev Food Sci Nutr; 2021; 61(2):337-355. PubMed ID: 32156153 [TBL] [Abstract][Full Text] [Related]
22. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. Barbara G; Zecchi L; Barbaro R; Cremon C; Bellacosa L; Marcellini M; De Giorgio R; Corinaldesi R; Stanghellini V J Clin Gastroenterol; 2012 Oct; 46 Suppl():S52-5. PubMed ID: 22955358 [TBL] [Abstract][Full Text] [Related]
23. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. Tojo R; Suárez A; Clemente MG; de los Reyes-Gavilán CG; Margolles A; Gueimonde M; Ruas-Madiedo P World J Gastroenterol; 2014 Nov; 20(41):15163-76. PubMed ID: 25386066 [TBL] [Abstract][Full Text] [Related]
24. The joint power of sex and stress to modulate brain-gut-microbiota axis and intestinal barrier homeostasis: implications for irritable bowel syndrome. Pigrau M; Rodiño-Janeiro BK; Casado-Bedmar M; Lobo B; Vicario M; Santos J; Alonso-Cotoner C Neurogastroenterol Motil; 2016 Apr; 28(4):463-86. PubMed ID: 26556786 [TBL] [Abstract][Full Text] [Related]
25. Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications. Natividad JM; Verdu EF Pharmacol Res; 2013 Mar; 69(1):42-51. PubMed ID: 23089410 [TBL] [Abstract][Full Text] [Related]
26. Regulation of Intestinal Immune Responses through TLR Activation: Implications for Pro- and Prebiotics. de Kivit S; Tobin MC; Forsyth CB; Keshavarzian A; Landay AL Front Immunol; 2014; 5():60. PubMed ID: 24600450 [TBL] [Abstract][Full Text] [Related]
27. Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies. Quigley EM Gastroenterol Clin North Am; 2011 Mar; 40(1):207-22. PubMed ID: 21333908 [TBL] [Abstract][Full Text] [Related]
28. Alterations in Intestinal Permeability: The Role of the "Leaky Gut" in Health and Disease. Stewart AS; Pratt-Phillips S; Gonzalez LM J Equine Vet Sci; 2017 May; 52():10-22. PubMed ID: 31000910 [TBL] [Abstract][Full Text] [Related]
29. Gut Goo: Physiology, Diet, and Therapy of Intestinal Mucus and Biofilms in Gastrointestinal Health and Disease. Damianos J; Abdelnaem N; Camilleri M Clin Gastroenterol Hepatol; 2024 Oct; ():. PubMed ID: 39426645 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis. Asha MZ; Khalil SFH Sultan Qaboos Univ Med J; 2020 Feb; 20(1):e13-e24. PubMed ID: 32190365 [TBL] [Abstract][Full Text] [Related]
31. Probiotics and inflammatory bowel diseases. Bai AP; Ouyang Q Postgrad Med J; 2006 Jun; 82(968):376-82. PubMed ID: 16754706 [TBL] [Abstract][Full Text] [Related]
32. Implication of Intestinal Barrier Dysfunction in Gut Dysbiosis and Diseases. Stolfi C; Maresca C; Monteleone G; Laudisi F Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203499 [TBL] [Abstract][Full Text] [Related]
33. Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options. Bonfrate L; Tack J; Grattagliano I; Cuomo R; Portincasa P Scand J Gastroenterol; 2013 Sep; 48(9):995-1009. PubMed ID: 23964766 [TBL] [Abstract][Full Text] [Related]
34. The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors. Lopetuso LR; Scaldaferri F; Bruno G; Petito V; Franceschi F; Gasbarrini A Eur Rev Med Pharmacol Sci; 2015; 19(6):1068-76. PubMed ID: 25855934 [TBL] [Abstract][Full Text] [Related]
35. Gut microbiota in chronic kidney disease. Cigarran Guldris S; González Parra E; Cases Amenós A Nefrologia; 2017; 37(1):9-19. PubMed ID: 27553986 [TBL] [Abstract][Full Text] [Related]
36. Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients. Matijašić M; Meštrović T; Perić M; Čipčić Paljetak H; Panek M; Vranešić Bender D; Ljubas Kelečić D; Krznarić Ž; Verbanac D Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27104515 [TBL] [Abstract][Full Text] [Related]
37. Mend Your Fences: The Epithelial Barrier and its Relationship With Mucosal Immunity in Inflammatory Bowel Disease. Martini E; Krug SM; Siegmund B; Neurath MF; Becker C Cell Mol Gastroenterol Hepatol; 2017 Jul; 4(1):33-46. PubMed ID: 28560287 [TBL] [Abstract][Full Text] [Related]
38. Irritable bowel syndrome: the role of the intestinal microbiota, pathogenesis and therapeutic targets. Dahlqvist G; Piessevaux H Acta Gastroenterol Belg; 2011 Sep; 74(3):375-80. PubMed ID: 22103040 [TBL] [Abstract][Full Text] [Related]
39. Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? Bringiotti R; Ierardi E; Lovero R; Losurdo G; Di Leo A; Principi M World J Gastrointest Pathophysiol; 2014 Nov; 5(4):550-9. PubMed ID: 25400998 [TBL] [Abstract][Full Text] [Related]
40. The effects of probiotics, prebiotics and synbiotics on the reduction of IBD complications, a periodic review during 2009-2020. Darb Emamie A; Rajabpour M; Ghanavati R; Asadolahi P; Farzi S; Sobouti B; Darbandi A J Appl Microbiol; 2021 Jun; 130(6):1823-1838. PubMed ID: 33098703 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]